-
Targeting the 8 kPa Prognostic Threshold: EBMT-EHA Thalassemia Gene Therapy Guideline Update Strengthens Precise Liver Risk Assessment
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Giuseppe De Franceschi from the University of Verona, Italy, representing the joint working group of the European Society for Blood and Marrow Transplantation (EBMT) and EHA, delivered an in-depth interpretation of the latest update to the “Guidelines for Patient Selection for Gene Therapy in Transfusion-Dependent…
-
ASCO China Voice | World’s First HOPE-07 Trial Launched: Disitamab Vedotin–Based Combination Poised to Redefine Perioperative Management of HER2-Expressing MIBC
Following the clinical success and approval of disitamab vedotin (RC48) plus toripalimab in locally advanced or metastatic urothelial carcinoma, attention has shifted toward improving outcomes for patients with muscle-invasive bladder cancer (MIBC) in the perioperative setting, where substantial unmet clinical needs remain.
-
ASCO China Voice | Prof. Junxing Chen: PUNCH03 Demonstrates Early Promise as Disitamab Vedotin Plus BCG Offers a New Chinese Strategy for High-Risk NMIBC
Transurethral resection of bladder tumor (TURBT) remains the standard treatment for non-muscle-invasive bladder cancer (NMIBC). However, up to 45% of patients experience tumor recurrence within one year following TURBT alone. Although intravesical therapies—including cytotoxic agents and immunotherapy—are widely used, substantial unmet clinical needs remain, underscoring the need for more effective treatment strategies.
-
ASCO 2026 | Prof. Pedro C. Barata: Safety and Dosimetry Results of TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan) in mCRPC
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting once again brought together the latest advances in cancer research from around the world. Among the most closely watched areas was radioligand therapy (RLT) for prostate cancer. During the meeting, the ProstACT Global 3 study team presented the first Part 1 results from its Phase…
-
ASCO 2026 | Prof. Li Mao: Ensartinib Differentiates Itself in the Global ALK Landscape and Accelerates Its International Expansion
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the treatment landscape for ALK-positive non-small cell lung cancer (NSCLC) continued to evolve, with major updates from landmark studies including CROWN, ALKOVE-1, and TRIDENT-1 reshaping global competition among ALK inhibitors.
-
2-Year PFS Rate Significantly Improved by 8.2%! FRONTMIND Study Confirms Tafa+Len+R-CHOP Improves Prognosis in Previously Untreated High-Risk DLBCL Patients
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Georg Lenz from the University of Münster, Germany, on behalf of the FRONTMIND study group, delivered an oral presentation on the final analysis results of the Phase 3 FRONTMIND study. This study aimed to investigate the efficacy and safety of adding the CD19 monoclonal antibody…
-
From Genetic Drivers to Precision Prevention: Professor George Vassiliou Awarded the EHA Research Excellence Award, Leading a Shift in Myeloid Malignancy Prevention and Treatment
At the 2026 European Hematology Association (EHA) Annual Meeting, the association presented the “EHA Research Excellence Award” to Professor George Vassiliou from the University of Cambridge and the Wellcome Sanger Institute, in recognition of his pioneering contributions to the fields of biology, pathogenesis, and early intervention in myeloid malignancies. In the subsequent award lecture, Professor…
-
Challenges and Perseverance: Large Randomized Controlled Trial Confirms ATG Superiority Over PTCy in Unrelated Donor HCT, Significantly Reducing Non-Relapse Mortality
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Johannes Schetelig from the Technical University Dresden and the German Bone Marrow Donor Center (DKMS) presented a highly anticipated Late-breaking Abstract. This study is a large-scale randomized controlled trial (RCT) designed to compare Anti-T Lymphocyte Globulin (ATLG) and Post-Transplant Cyclophosphamide (PTCy) “head-to-head” for the prophylaxis…
Connecting Medical Expertise through Media